{"id":"havrix720","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Injection site soreness"},{"rate":"10-20","effect":"Headache"},{"rate":"5-15","effect":"Fatigue"},{"rate":"5-10","effect":"Myalgia"},{"rate":"1-5","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL3697386","moleculeType":"Small molecule","molecularWeight":"407.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated (killed) hepatitis A virus antigen, which triggers both humoral and cellular immune responses without causing disease. This leads to the production of protective anti-HAV antibodies and immunological memory, conferring long-term immunity against hepatitis A infection. The 720 designation refers to the antigen content (720 ELISA units per 0.5 mL dose).","oneSentence":"Havrix 720 is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:38.209Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis A infection in adults and children"}]},"trialDetails":[{"nctId":"NCT01041573","phase":"PHASE3","title":"Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-03","conditions":"Encephalitis","enrollment":1869},{"nctId":"NCT01307436","phase":"PHASE3","title":"Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccines","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2007-03-14","conditions":"Hepatitis A","enrollment":327},{"nctId":"NCT01405677","phase":"PHASE2","title":"Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2004-06","conditions":"Hepatitis A","enrollment":308}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Havrix®720","genericName":"Havrix®720","companyName":"Valneva Austria GmbH","companyId":"valneva-austria-gmbh","modality":"Biologic","firstApprovalDate":"","aiSummary":"Havrix 720 is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus. Used for Prevention of hepatitis A infection in adults and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}